Cleveland Clinic's Gene Therapy Achieves 52.5% Reduction in LDL Cholesterol

Buzzline

A novel CRISPR-Cas9 therapy, designed and evaluated at Cleveland Clinic, has demonstrated significant and sustained decreases in detrimental blood lipids following a single treatment. In a Phase 1 clinical trial with 15 participants suffering from lipid disorders unresponsive to conventional medications, the top administered dose resulted in a 52.5% drop in LDL cholesterol and a 47.8% decrease in triglycerides after one year. This therapy, known as CTX310, functions by modifying the ANGPTL3 gene in the liver, which plays a crucial role in lipid regulation. Throughout the year-long follow-up, no severe adverse events linked to the treatment were observed. Further extensive studies and prolonged observation will be necessary to fully evaluate the therapy's safety and efficacy.  Disclosure: This video contains stock footage and content created or enhanced using Al-assisted tools. ai-generated

Transcript

00:00An experimental gene-editing treatment is showing promising results for high cholesterol.

00:04The therapy, called CTX310, was tested in an early human trial at Cleveland Clinic.

00:10It uses CRISPR-Cas9 technology to switch off the ANGPTL3 gene in the liver.

00:16That gene helps regulate cholesterol and other blood fats.

00:19The Phase I study included 15 patients with medication-resistant lipid disorders.

00:24Participants received a single infusion of CTX310 at different doses.

00:29Researchers then tracked cholesterol levels and treatment safety for one year.

00:33At the highest dose, LDL cholesterol fell 52.5% from pretreatment levels.

00:39Triglycerides also dropped by 47.8% after 12 months.

00:43Researchers reported that these reductions persisted throughout the year.

00:47No serious adverse events linked to the treatment were reported.

00:51However, the study was small and designed primarily to assess early safety.

00:56Larger trials will be needed to determine how effective the therapy is.

01:00Participants will also receive long-term safety monitoring for 15 years.

01:04The findings could help shape future approaches to treating difficult cholesterol disorders.

01:09Disclosure.

01:10This video contains stock footage and content created or enhanced using AI-assisted tools.

01:14This video contains no dehutions.

01:15That DNA could help shape future

Category

Transcript

Comments

Recommended